Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 3/20 | 0.43 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402921 | 0.83 | KDM4E (0.47) | NQO1VKORC1CYP2C9KDM4EALDH1A1 | |
| SCHEMBL7400476 | 0.80 | NQO1 (0.47) | NQO1VKORC1CYP2C9MEN1KMT2A | |
| SCHEMBL7405056 | 0.80 | NQO1 (0.43) | NQO1VKORC1CYP2C9KDM4EALDH1A1 | |
| SCHEMBL7403395 | 0.80 | KCNK3 (0.31) | CYP2C9 | |
| SCHEMBL7400467 | 0.79 | NQO1 (0.43) | NQO1VKORC1CYP2C9TOP1 | |
| SCHEMBL7403207 | 0.79 | NQO1 (0.42) | NQO1VKORC1CYP2C9TOP1 | |
| SCHEMBL7400960 | 0.79 | NQO1 (0.42) | NQO1VKORC1CYP2C9KDM4EALDH1A1 | |
| SCHEMBL7403398 | 0.79 | PDE4A (0.32) | CYP2C9HSD17B10MEN1KMT2A | |
| SCHEMBL7404034 | 0.79 | NQO1 (0.41) | NQO1VKORC1CYP2C9KDM4EALDH1A1 | |
| SCHEMBL8807790 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | 712 NORTH INC. (US) | 2024-05-28 | — | — | US | claimed |
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | 712 NORTH INC. | 2021-08-12 | — | — | US | claimed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | claimed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | claimed |
| CN-1749252-B | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2011-06-08 | — | — | CN | disclosed |
| CN-1329378-C | Compounds for the treatment of retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1749252-A | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | CN | disclosed |
| CN-1539825-A | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-10-27 | — | — | CN | disclosed |
| CN-1154642-C | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-06-23 | — | — | CN | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | OPA1, OLA1, PITRM1 | NQO1 121/4885VKORC1 245/4885CYP2C9 3003/4885 |
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | OPA1, OLA1, PITRM1 | NQO1 121/4885VKORC1 245/4885CYP2C9 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.